Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06043674 | Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation | recruiting | Phase 2 | 70 | Christine RyanOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07014917 | Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL(ESR-23-22182) | recruiting | Phase 2 | 62 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | recruiting | Phase 2 | 22 | Zulfa OmerOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT01853631 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)(SAGAN) | recruiting | Phase 1 | 64 | Baylor College of MedicineOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05722405 | Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | recruiting | Phase 4 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06054776 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 31 | Medical College of WisconsinOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07313982 | LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION(LLC/LEF1 2024) | recruiting | — | 350 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04991103 | Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | recruiting | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07312188 | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 90 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05816850 | Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial(FIL_FOLL-BIO) | recruiting | — | 654 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06588205 | Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma(FIL_MIMYC) | recruiting | — | 200 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07100067 | LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 35 | Nanjing Legend Biotech Co.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05642884 | Prehabilitation Feasibility Among Older Adults Undergoing Transplantation | recruiting | N/A | 30 | Noha Mohamed SharafeldinOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05695508 | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5(HD10/DSMMXX) | recruiting | Phase 2 | 160 | University of Heidelberg Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06247189 | ICOPE Program Feasibility in the Management of Myeloma Patients(Onco-ICOPE) | recruiting | N/A | 30 | University Hospital, ToulouseOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07296627 | Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients(PRIMARY) | recruiting | — | 500 | Peking University People's HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06736613 | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06757647 | Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 61 | Seema BhatOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 150 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07283822 | Amping up With PemJAK | recruiting | Phase 2 | 53 | Seda S. ToluOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma(IMCL-2023) | recruiting | Phase 2 | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 2 | Dec 16, 2025 | clinicaltrials |
| NCT04268199 | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment(EASE) | recruiting | Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02863692 | Registry of the German CLL Study Group(CLL-Registry) | recruiting | — | 8,000 | German CLL Study GroupOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05556928 | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry(CARE-Heme) | recruiting | — | 5,000 | University of Alabama at BirminghamOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | recruiting | Phase 2 | 30 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06390956 | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | recruiting | Phase 2 | 23 | University of UtahOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04844528 | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers | recruiting | Phase 2 | 86 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT06485076 | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma(EPC-MM+L) | recruiting | N/A | 144 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06645678 | Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma(MELT-MM) | recruiting | Phase 1 / Phase 2 | 75 | YOUNGIL KOHOTHER | 2 | Dec 3, 2025 | clinicaltrials |
| NCT06920251 | Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy(OPTIMUS-EL) | recruiting | Phase 2 | 40 | Seoul National University HospitalOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06947083 | Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | recruiting | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07162012 | Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma(Anti-EBV TCR-T) | recruiting | Early Phase 1 | 24 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257510 | Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma | recruiting | N/A | 34 | Peking University Third HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT00898235 | Collection of Samples and Clinical Data From Patients With Amyloid Diseases | recruiting | — | 10,000 | Boston Medical CenterOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05312255 | Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma | recruiting | N/A | 175 | Roswell Park Cancer InstituteOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07248176 | Universal CAR-T Cell Therapy for MM | recruiting | N/A | 6 | Bioray LaboratoriesINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07188090 | Mozobil for Autologous Hematopoietic Stem Cell Transplantation(HSCT) | recruiting | Phase 2 | 100 | Thomas Jefferson UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 7, 2026source: clinicaltrials